Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred. This is not always available due to financial restrictions. This study explores the possibility of post implant US-CT fusion to improve contouring accuracy and potentially replace the use of MR-CT fusion.
25 participants undergoing permanent seed prostate brachytherapy will be approached to undergo collection of prostate US images at the completion of their procedure. This will add approximately 5 minutes to the duration of their brachytherapy procedure. The US study will not entail any discomfort or risk to participants as they are still under anesthesia for the implant procedure. The institution standard of care for quality assurance will be complied with, obtaining a CT and MRI of the prostate at 30 days after the procedure. These will be co-registered and analyzed in the normal fashion. In addition, the post implant US images will also be co-registered with the CT and the resulting dosimetric parameters compared.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| transrectal ultrasound | Diagnostic Test | Use of US for post implant quality assessment |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of prostate dosimetry assessed by US-CT fusion with respect to the standard MR-CT fusion | Dosimetry will be calculated using 2 different imaging modalities (US vs MRI) and compared | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of prostate volume assessed by 2 different imaging modalities | Assessment of prostate volume as contoured on US vs MRI post implant | 1 month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Consecutive patients undergoing prostate brachytherapy for localized prostate cancer.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Francois Bachand, MD | BC Cancer | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| BC Cancer | Kelowna | British Columbia | V1Y5L3 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 28, 2021 | |
| Reset | Jun 22, 2021 | |
| Release | Jun 25, 2021 | |
| Reset | Jul 15, 2021 | |
| Release | Jul 26, 2021 | |
| Reset | Aug 20, 2021 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 28, 2021 | Jun 22, 2021 | |||
| Jun 25, 2021 |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Jul 15, 2021 |
| Jul 26, 2021 | Aug 20, 2021 |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |